GSK announces top antimicrobial resistance benchmark report

GSK has announced their new welcomes independent recognition of leadership in addressing the urgent global threat of antimicrobial resistance in the AMR Benchmark Report, issued today. GSK’s leading position among large biopharma companies reflects our continuous focus on delivering innovative antibiotic medicines and vaccines for patients where there is significant unmet medical need.

Tony Wood, Chief Scientific Officer, GSK, said: “Antimicrobial resistance is one of the most pressing scientific and medical challenges of our time, and we urgently need new medicines and vaccines for resistant infections. GSK is using cutting-edge technology to bring much-needed innovation to patients, including a new first-in-class antibiotic last year. While this is welcome progress, it is not enough and today’s report underlines the need for governments and industry to work together to improve economic incentivisation of R&D and implement better access and stewardship models.”

Note that GSK has the strongest R&D pipeline of AMR-relevant medicines and vaccines in development of any company assessed, and the most R&D projects targeting high-priority drug-resistant pathogens in need of new treatments.

GSK has recently secured approval of the first new oral antibiotic class for uncomplicated urinary tract infections in nearly 30 years, filed for regulatory approval for another new treatment, and announced six major new research programmes with the Fleming Initiative to find new ways to slow the progress of AMR using AI.

---

---

Related Topics and Keywords

antimicrobial resistance, GSK